Literature DB >> 20116399

Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance.

Claudia F Althaus1, Sara Gianella, Philip Rieder, Viktor von Wyl, Roger D Kouyos, Barbara Niederöst, Adrian Schmid, Karin J Metzner, Beda Joos, Huldrych F Günthard, Marek Fischer.   

Abstract

Quantitative PCR (qPCR) using fluorescent hydrolysis probes (FH-probes; TaqMan-probes) of variable genomes, such as HIV-1, can result in underestimation of viral copy numbers due to mismatches in the FH-probe's target sequences. Therefore both target conservation and physical properties of FH-probes, such as melting temperature, baseline fluorescence and secondary structure, should be considered in design of FH-probes. Analysis of a database of 1242 near full-length HIV-1 sequences with a novel computational tool revealed that the probability of target and FH-probe identity decreases exponentially with FH-probe length. In addition, this algorithm allowed for identification of continuous sequence stretches of high conservation, from which FH-probes with global HIV-1 clade coverage could be chosen. To revise the prerequisites of physical FH-probe function, properties of 30 DNA and 21 chimeric DNA locked nucleic acid (DLNA) HIV-1 FH-probes were correlated with their performance in qPCR. This identified the presence of stable secondary structures within FH-probes and the base composition and thermal stability of the 5' proximal end as novel predictors of FH-probe performance. Thus, empirically validated novel principles of FH-probe design regarding conservation and qPCR-performance were identified, which complement and extend current rules for FH-probe design. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20116399     DOI: 10.1016/j.jviromet.2010.01.012

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  24 in total

1.  Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract.

Authors:  Sara Gianella; Sheldon R Morris; Christy Anderson; Celsa A Spina; Milenka V Vargas; Jason A Young; Douglas D Richman; Susan J Little; Davey M Smith
Journal:  AIDS       Date:  2013-01-02       Impact factor: 4.177

2.  Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.

Authors:  Peilin Li; Theodore Ruel; Katsuya Fujimoto; Hiroyu Hatano; Steven Yukl; Leigh Anne Eller; Teri Liegler; Moses Kamya; Anne Gassasira; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong
Journal:  J Virol Methods       Date:  2010-09-21       Impact factor: 2.014

3.  Cytomegalovirus DNA in semen and blood is associated with higher levels of proviral HIV DNA.

Authors:  Sara Gianella; Christy M Anderson; Milenka V Vargas; Douglas D Richman; Susan J Little; Sheldon R Morris; Davey M Smith
Journal:  J Infect Dis       Date:  2012-12-28       Impact factor: 5.226

4.  Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Sara Gianella; Elizabeth Sinclair; Lorrie Epling; Qingsheng Li; Lijie Duan; Alex L M Choi; Valerie Girling; Terence Ho; Peilin Li; Katsuya Fujimoto; Harry Lampiris; C Bradley Hare; Mark Pandori; Ashley T Haase; Huldrych F Günthard; Marek Fischer; Amandeep K Shergill; Kenneth McQuaid; Diane V Havlir; Joseph K Wong
Journal:  J Infect Dis       Date:  2010-10-12       Impact factor: 5.226

5.  Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals.

Authors:  Kersten K Koelsch; Thomas A Rasmussen; William J Hey-Nguyen; Chester Pearson; Yin Xu; Michelle Bailey; Katherine H Marks; Sarah C Sasson; Mark S Taylor; Robyn Tantau; Solange Obeid; Brad Milner; Orla Morrissey; Angie N Pinto; Kazuo Suzuki; Michael P Busch; Sheila M Keating; Philipp Kaiser; Steven Yukl; Joseph K Wong; Bonnie M Hiener; Sarah Palmer; John Zaunders; Jeffrey J Post; Derek J Chan; Sharon Avery; Sam T Milliken; Anthony D Kelleher; Sharon R Lewin; David A Cooper
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.731

6.  Longitudinal Viral Dynamics in Semen During Early HIV Infection.

Authors:  Sheldon R Morris; Mitchell Zhao; Davey M Smith; Milenka V Vargas; Susan J Little; Sara Gianella
Journal:  Clin Infect Dis       Date:  2017-02-15       Impact factor: 9.079

7.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

8.  Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection.

Authors:  Adrian Schmid; Sara Gianella; Viktor von Wyl; Karin J Metzner; Alexandra U Scherrer; Barbara Niederöst; Claudia F Althaus; Philip Rieder; Christina Grube; Beda Joos; Rainer Weber; Marek Fischer; Huldrych F Günthard
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

9.  The Molecular Characterization of Intestinal Explant HIV Infection Using Polymerase Chain Reaction-Based Techniques.

Authors:  Laura Janocko; Andrew D Althouse; Rhonda M Brand; Ross D Cranston; Ian McGowan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-08-24       Impact factor: 2.205

10.  Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.

Authors:  Josué Pérez-Santiago; Sara Gianella; Marta Massanella; Celsa A Spina; Maile Y Karris; Susanna R Var; Derek Patel; Parris S Jordan; Jason A Young; Susan J Little; Douglas D Richman; Davey M Smith
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.